Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sanofi Completes Vicebio $1.6B Acquisition, Adds RSV Vaccine Platform

Fineline Cube Dec 5, 2025
Company Deals

Formosa Pharma APP13007 Clobetasol ASEAN Deal with Rxilient

Fineline Cube Dec 5, 2025
Company Deals

Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes

Fineline Cube Dec 4, 2025
Company Deals R&D

Bio-Sincerity UCAS R&D Center Pharma Synthesis

Fineline Cube Dec 4, 2025
Company Deals

Simcere deuremidevir RSV Licensing Deal Targets China Breakthrough

Fineline Cube Dec 4, 2025
Policy / Regulatory

NHSA Guangzhou Drug-List Conference Releases 2025 Medical Insurance Formulary

Fineline Cube Dec 4, 2025
Company Drug

Juventas CAR-T LBCL Launch Marks Second Indication

Fineline Cube Dec 5, 2025
Company Drug

BMS Breyanzi MZL FDA Approval First CAR-T

Fineline Cube Dec 5, 2025
Policy / Regulatory

Fujian Procurement Center Announces VBP for Cardiac and Laparoscopic Medical Consumables

Fineline Cube Oct 21, 2022

The Fujian drug and device joint procurement center has released two separate notifications regarding the...

Policy / Regulatory

NMPA Releases 61st Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Oct 21, 2022

The National Medical Products Administration (NMPA) has released the 61st batch of reference drugs for...

Company Drug

Betta Pharmaceuticals’ BPI-460372 Accepted for Clinical Trial Review by NMPA

Fineline Cube Oct 21, 2022

China’s Betta Pharmaceuticals (SHE: 300558) has announced that its clinical trial filing for the Category...

Company Drug

Frontier Biotechnologies Secures Approval for HIV Therapy Alfusid

Fineline Cube Oct 21, 2022

Nanjing-based Frontier Biotechnologies Inc. has announced that its supplementary market filing for Alfusid (albuvirtide), China’s...

Company Drug

Hengrui’s Camrelizumab and Akeso’s AK112 Set to Receive Breakthrough Designation in China

Fineline Cube Oct 21, 2022

The Center for Drug Evaluation (CDE) website indicates that China-based Jiangsu Hengrui Medicine Co., Ltd’s...

Company Drug

China Approves GSK’s Juluca for HIV-1 Infection

Fineline Cube Oct 21, 2022

The National Medical Products Administration (NMPA) has approved the market application for GlaxoSmithKline’s (GSK, NYSE:...

Company Drug

Hengrui Medicine Files for Dalpiciclib as Initial Therapy for Breast Cancer

Fineline Cube Oct 21, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced a supplementary market filing for...

Company Deals

HitGen Partners with C4X Discovery to Identify Novel Inflammatory Disease Treatments

Fineline Cube Oct 20, 2022

China-based HitGen Inc. (SHA: 688222) has announced a partnership with UK-headquartered C4X Discovery Holdings plc...

Company

Abbott Reports Q3 Sales Growth, Raises Full-Year EPS Guidance

Fineline Cube Oct 20, 2022

With the Q3 2022 reporting season underway, US-based medtech giant Abbott (NYSE: ABT) released its...

Company Policy / Regulatory

Shaanxi Releases Notice for Inter-Provincial Orthodontic Brackets VBP

Fineline Cube Oct 20, 2022

The Shaanxi Public Resources Trading Center has released the “Inter-provincial Alliance (regions, Corps) Orthodontic Brackets...

Company Drug

Hainan Poly Pharm’s Generic Ganciclovir Approved in Sweden for CMV Retinitis

Fineline Cube Oct 20, 2022

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced receiving technical review approval from...

Company Drug

Bio-Thera’s BAT1806 Biosimilar Accepted for Review by European Medicine Agency

Fineline Cube Oct 20, 2022

China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that a Biologic License Application (BLA) for...

Company Deals

Kactus Biosystems Raises RMB 200M in Series B Financing for Protein and Enzyme Development

Fineline Cube Oct 20, 2022

Kactus Biosystems, a Shanghai-based firm specializing in target proteins and raw enzymes, has raised RMB...

Company Deals

Shandong Junxiu Biotechnology Secures RMB 45M in Series B Financing

Fineline Cube Oct 20, 2022

Shandong Junxiu Biotechnology Co., Ltd, a China-based maker of implantable regenerative medicine devices, has raised...

Company Drug

Brii Biosciences Reports Positive Phase I Results for HIV Treatments BRII-732 and BRII-778

Fineline Cube Oct 20, 2022

China-based Brii Biosciences Limited (HKG: 2137) has published the latest results of two Phase I...

Company

Bayer to Set Up Shenzhen Unit to Boost Women’s Healthcare in South China

Fineline Cube Oct 19, 2022

Bayer’s (ETR: BAYN) women’s healthcare unit for the South China region is reportedly planning to...

Company Drug

GenScript’s Legend Biotech Reports USD 55M in Carvykti Sales

Fineline Cube Oct 19, 2022

China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has revealed that sales of...

Company Drug

YiChang HEC ChangJiang Pharma’s Insulin Aspart Gains NMPA Approval

Fineline Cube Oct 19, 2022

China-based firm YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced that its in-house...

Company Drug

Henlius Biotech’s Hanbeitai Gains NMPA Approval for Recurrent Glioblastoma

Fineline Cube Oct 19, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that a supplementary Biologic License Application (sBLA)...

Company Policy / Regulatory

NHSA Responds to Proposal on Dental Implants’ Inclusion in NRDL

Fineline Cube Oct 19, 2022

The National Healthcare Security Administration (NHSA) has responded to the No. 6184 suggestion from the...

Posts pagination

1 … 541 542 543 … 594

Recent updates

  • Sanofi Completes Vicebio $1.6B Acquisition, Adds RSV Vaccine Platform
  • Juventas CAR-T LBCL Launch Marks Second Indication
  • BMS Breyanzi MZL FDA Approval First CAR-T
  • Formosa Pharma APP13007 Clobetasol ASEAN Deal with Rxilient
  • Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Sanofi Completes Vicebio $1.6B Acquisition, Adds RSV Vaccine Platform

Company Drug

Juventas CAR-T LBCL Launch Marks Second Indication

Company Drug

BMS Breyanzi MZL FDA Approval First CAR-T

Company Deals

Formosa Pharma APP13007 Clobetasol ASEAN Deal with Rxilient

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.